PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI, DEMONSTRATES DEEP AND DURABLE TG REDUCTIONS IN PATIENTS WITH SHTG, SHASTA-2 FINAL RESULTS

• Autore principale: Nathalie Kertesz, PhD (Autore)
• Natura: Libro
• Pubblicazione: Elsevier, 2024-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Therapeutic Area: Pharmacologic Therapy Background: Individuals with severe hypertriglyceridemia have an increased acute pancreatitis (AP) risk. Current treatments fail to lower TGs below a threshold that exposes patients to the risk of AP. Plozasiran, a hepatocyte-targeted siRNA reduces circulating...